Natera, Inc. (NTRA)
USD 156.66
(3.5%)
USD 156.66
(3.5%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.45 Billion USD | 4.49% |
| 2022 | 1.39 Billion USD | 12.78% |
| 2021 | 1.23 Billion USD | 32.65% |
| 2020 | 932.15 Million USD | 59.98% |
| 2019 | 582.65 Million USD | 117.27% |
| 2018 | 268.17 Million USD | 50.0% |
| 2017 | 178.77 Million USD | -15.14% |
| 2016 | 210.68 Million USD | -20.57% |
| 2015 | 265.24 Million USD | 114.56% |
| 2014 | 123.62 Million USD | 106.99% |
| 2013 | 59.72 Million USD | 355.87% |
| 2012 | 13.1 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.51 Billion USD | 3.32% |
| 2024 Q1 | 1.46 Billion USD | 0.76% |
| 2023 FY | 1.45 Billion USD | 4.49% |
| 2023 Q2 | 1.24 Billion USD | -5.38% |
| 2023 Q3 | 1.44 Billion USD | 15.92% |
| 2023 Q1 | 1.31 Billion USD | -5.42% |
| 2023 Q4 | 1.45 Billion USD | 0.73% |
| 2022 Q4 | 1.39 Billion USD | 38.19% |
| 2022 Q3 | 1 Billion USD | -5.42% |
| 2022 FY | 1.39 Billion USD | 12.78% |
| 2022 Q1 | 1.14 Billion USD | -7.43% |
| 2022 Q2 | 1.06 Billion USD | -6.79% |
| 2021 FY | 1.23 Billion USD | 32.65% |
| 2021 Q1 | 893.51 Million USD | -4.15% |
| 2021 Q2 | 849.95 Million USD | -4.87% |
| 2021 Q3 | 1.31 Billion USD | 54.29% |
| 2021 Q4 | 1.23 Billion USD | -5.71% |
| 2020 Q4 | 932.15 Million USD | -4.56% |
| 2020 Q2 | 723.26 Million USD | 29.47% |
| 2020 Q1 | 558.63 Million USD | -4.12% |
| 2020 FY | 932.15 Million USD | 59.98% |
| 2020 Q3 | 976.71 Million USD | 35.04% |
| 2019 Q4 | 582.65 Million USD | 53.23% |
| 2019 FY | 582.65 Million USD | 117.27% |
| 2019 Q3 | 380.25 Million USD | -0.8% |
| 2019 Q2 | 383.32 Million USD | 46.62% |
| 2019 Q1 | 261.44 Million USD | -2.51% |
| 2018 Q4 | 268.17 Million USD | -3.3% |
| 2018 FY | 268.17 Million USD | 50.0% |
| 2018 Q1 | 218.65 Million USD | 22.31% |
| 2018 Q2 | 194.36 Million USD | -11.11% |
| 2018 Q3 | 277.3 Million USD | 42.68% |
| 2017 FY | 178.77 Million USD | -15.14% |
| 2017 Q4 | 178.77 Million USD | -12.39% |
| 2017 Q3 | 204.05 Million USD | 28.8% |
| 2017 Q2 | 158.42 Million USD | -10.0% |
| 2017 Q1 | 176.02 Million USD | -16.45% |
| 2016 Q3 | 242.38 Million USD | -7.23% |
| 2016 Q2 | 261.26 Million USD | -1.69% |
| 2016 Q1 | 265.74 Million USD | 0.19% |
| 2016 Q4 | 210.68 Million USD | -13.08% |
| 2016 FY | 210.68 Million USD | -20.57% |
| 2015 Q4 | 265.24 Million USD | 1.1% |
| 2015 Q3 | 262.36 Million USD | 145.77% |
| 2015 Q2 | 106.75 Million USD | -11.12% |
| 2015 FY | 265.24 Million USD | 114.56% |
| 2015 Q1 | 120.1 Million USD | -2.85% |
| 2014 FY | 123.62 Million USD | 106.99% |
| 2014 Q1 | 58.21 Million USD | -2.52% |
| 2014 Q3 | 56.62 Million USD | 0.0% |
| 2014 Q4 | 123.62 Million USD | 118.31% |
| 2013 FY | 59.72 Million USD | 355.87% |
| 2013 Q1 | - USD | 0.0% |
| 2013 Q4 | 59.72 Million USD | 0.0% |
| 2012 FY | 13.1 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -638.14% |
| Biodesix, Inc. | 99.09 Million USD | -1370.418% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -17623.235% |
| Castle Biosciences, Inc. | 477.81 Million USD | -204.958% |
| DarioHealth Corp. | 96.38 Million USD | -1411.713% |
| Exact Sciences Corporation | 6.47 Billion USD | 77.483% |
| IDEXX Laboratories, Inc. | 3.25 Billion USD | 55.302% |
| Illumina, Inc. | 10.11 Billion USD | 85.589% |
| Intelligent Bio Solutions Inc. | 13.77 Million USD | -10475.074% |
| iSpecimen Inc. | 15.81 Million USD | -9111.154% |
| Standard BioTools Inc. | 323.06 Million USD | -351.029% |
| 23andMe Holding Co. | 395.16 Million USD | -268.737% |
| Medpace Holdings, Inc. | 1.65 Billion USD | 12.053% |
| NeoGenomics, Inc. | 1.68 Billion USD | 13.33% |
| Inotiv, Inc. | 856.53 Million USD | -70.12% |
| Psychemedics Corporation | 13.27 Million USD | -10880.595% |
| Prenetics Global Limited | 254.17 Million USD | -473.286% |
| Precipio, Inc. | 18.1 Million USD | -7949.97% |
| RadNet, Inc. | 2.88 Billion USD | 49.523% |
| Sotera Health Company | 3.13 Billion USD | 53.453% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -1575.357% |
| Exagen Inc. | 56.94 Million USD | -2458.874% |
| Aspira Women's Health Inc. | 6.26 Million USD | -23169.323% |
| Neogen Corporation | 4.58 Billion USD | 68.214% |
| Myriad Genetics, Inc. | 1.19 Billion USD | -21.559% |
| ICON Public Limited Company | 16.98 Billion USD | 91.424% |
| Bionano Genomics, Inc. | 214.4 Million USD | -579.617% |
| CareDx, Inc | 484.61 Million USD | -200.677% |
| Check-Cap Ltd. | 25.01 Million USD | -5724.539% |
| Twist Bioscience Corporation | 776.4 Million USD | -87.676% |
| Guardant Health, Inc. | 1.78 Billion USD | 18.433% |
| BioNexus Gene Lab Corp. | 11.39 Million USD | -12682.03% |
| Fulgent Genetics, Inc. | 1.27 Billion USD | -14.454% |
| Sera Prognostics, Inc. | 95.44 Million USD | -1426.729% |
| OPKO Health, Inc. | 2.01 Billion USD | 27.567% |
| Personalis, Inc. | 225.09 Million USD | -547.326% |
| Applied DNA Sciences, Inc. | 13.65 Million USD | -10573.675% |
| Star Equity Holdings, Inc. | 86.97 Million USD | -1575.357% |
| MDxHealth SA | 129.13 Million USD | -1028.4% |
| Prenetics Global Limited | 254.17 Million USD | -473.286% |
| ENDRA Life Sciences Inc. | 6.75 Million USD | -21473.786% |
| Mainz Biomed B.V. | 15.4 Million USD | -9356.307% |
| Trinity Biotech plc | 59.43 Million USD | -2351.628% |
| Neuronetics, Inc. | 115.83 Million USD | -1157.975% |
| bioAffinity Technologies, Inc. | 8.22 Million USD | -17623.235% |